Depakine safety check: did doctors get the memo?
NCT ID NCT06714448
First seen Mar 10, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study looked at whether safety information about the epilepsy drug Depakine (sodium valproate) is reaching doctors and pharmacists in Saudi Arabia. Researchers surveyed 455 healthcare professionals to see if they read the materials and know how to use the drug safely. No patients received any treatment or extra visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
Conditions
Explore the condition pages connected to this study.